Loading...

Novo Nordisk A/S Peer Comparison

Metric Value Ranking
Market Cap $486.3 Billion 1/21 NVO
$486.3B
VRTX
$121.6B
REGN
$89.9B
SGEN
$43.2B
ALNY
$34.8B
BNTX
$25.9B
MRNA
$20.6B
BMRN
$12.6B
SRPT
$11.7B
MDGL
$7.2B
RETA
$6.6B
CRSP
$4.3B
TGTX
$3.8B
NTLA
$1.5B
NVAX
$1.5B
ICPT
$794.7M
CVAC
$607.9M
TERN
$599.5M
DNA
$424.0M
HEPA
$3.7M
CWBR
$1.4M
Gross Margin 85% 8/21 ICPT
100%
RETA
96%
MDGL
96%
NVAX
91%
ALNY
90%
TGTX
89%
VRTX
86%
NVO
85%
SRPT
85%
REGN
83%
BMRN
80%
SGEN
75%
NTLA
63%
BNTX
54%
DNA
45%
MRNA
35%
CWBR
0%
HEPA
0%
TERN
0%
CRSP
-100%
CVAC
-100%
Profit Margin 29% 4/21 RETA
100%
REGN
40%
NVAX
39%
NVO
29%
BMRN
15%
TGTX
9%
SRPT
2%
CWBR
0%
HEPA
0%
TERN
0%
ALNY
-3%
ICPT
-3%
SGEN
-33%
VRTX
-100%
MDGL
-100%
NTLA
-100%
CRSP
-100%
MRNA
-100%
BNTX
-100%
CVAC
-100%
DNA
-100%
EBITDA margin 51% 1/21 NVO
51%
NVAX
42%
REGN
34%
BMRN
18%
TGTX
12%
ALNY
10%
SRPT
3%
ICPT
-3%
SGEN
-34%
CWBR
-100%
HEPA
-100%
TERN
-100%
VRTX
-132%
DNA
-237%
RETA
-356%
CVAC
-474%
BNTX
-505%
MRNA
-549%
MDGL
-1110%
NTLA
-1961%
CRSP
-28320%
Quarterly Revenue $10.0 Billion 1/21 NVO
$10.0B
REGN
$3.5B
VRTX
$2.6B
BMRN
$708.7M
ALNY
$659.8M
SGEN
$648.7M
NVAX
$415.5M
SRPT
$362.9M
MRNA
$241.0M
BNTX
$142.1M
ICPT
$88.8M
TGTX
$73.5M
DNA
$56.2M
RETA
$22.7M
CVAC
$15.9M
MDGL
$14.6M
NTLA
$7.0M
CRSP
$517,000
CWBR
$0
HEPA
$0
TERN
$0
Quarterly Earnings $3.0 Billion 1/21 NVO
$3.0B
REGN
$1.4B
RETA
$193.0M
NVAX
$162.4M
BMRN
$107.2M
TGTX
$6.9M
SRPT
$6.5M
ICPT
-$2.8M
HEPA
-$3.9M
CWBR
-$4.3M
ALNY
-$16.9M
TERN
-$22.7M
CVAC
-$80.1M
CRSP
-$126.4M
NTLA
-$147.0M
MDGL
-$152.0M
SGEN
-$215.8M
DNA
-$217.2M
BNTX
-$892.2M
MRNA
-$1.3B
VRTX
-$3.6B
Quarterly Free Cash Flow $5.5 Billion 1/21 NVO
$5.5B
BNTX
$1.6B
NVAX
$311.1M
REGN
$143.1M
ALNY
$116.1M
BMRN
$96.9M
TGTX
$5.5M
ICPT
$3.9M
MDGL
-$0
CWBR
-$1.8M
HEPA
-$10.9M
SRPT
-$14.2M
TERN
-$16.2M
NTLA
-$59.2M
RETA
-$70.2M
SGEN
-$79.8M
CRSP
-$96.3M
CVAC
-$105.8M
DNA
-$111.4M
MRNA
-$1.5B
VRTX
-$3.8B
Trailing 4 Quarters Revenue $38.1 Billion 2/21 BMRN
$648.1B
NVO
$38.1B
REGN
$13.5B
VRTX
$10.3B
MRNA
$5.1B
BNTX
$3.0B
ALNY
$2.3B
SGEN
$2.3B
SRPT
$1.5B
NVAX
$822.7M
TGTX
$346.7M
ICPT
$317.7M
CRSP
$201.0M
DNA
$184.3M
CVAC
$71.8M
NTLA
$46.0M
RETA
$24.4M
MDGL
$14.6M
CWBR
$0
HEPA
$0
TERN
$0
Trailing 4 Quarters Earnings $13.3 Billion 2/21 NVO
$10.0B
REGN
$3.5B
VRTX
$2.6B
BMRN
$708.7M
ALNY
$659.8M
SGEN
$648.7M
NVAX
$415.5M
SRPT
$362.9M
MRNA
$241.0M
BNTX
$142.1M
ICPT
$88.8M
TGTX
$73.5M
DNA
$56.2M
RETA
$22.7M
CVAC
$15.9M
MDGL
$14.6M
NTLA
$7.0M
CRSP
$517,000
CWBR
-$0
HEPA
-$0
TERN
-$0
Quarterly Earnings Growth 3% 9/21 RETA
362%
NVAX
180%
SRPT
127%
TGTX
114%
ALNY
94%
HEPA
72%
REGN
48%
MRNA
7%
NVO
3%
CVAC
-8%
SGEN
-13%
NTLA
-19%
DNA
-25%
TERN
-27%
CWBR
-59%
CRSP
-63%
MDGL
-77%
BMRN
-100%
ICPT
-101%
BNTX
-326%
VRTX
-492%
Annual Earnings Growth 14% 8/21 TGTX
159%
SRPT
103%
ALNY
91%
RETA
72%
NVAX
64%
HEPA
47%
REGN
26%
NVO
14%
CWBR
1%
CRSP
-12%
DNA
-14%
CVAC
-15%
TERN
-16%
SGEN
-26%
NTLA
-27%
MDGL
-60%
BMRN
-63%
VRTX
-116%
ICPT
-124%
BNTX
-139%
MRNA
-413%
Quarterly Revenue Growth 25% 7/21 RETA
2885%
TGTX
357%
ALNY
107%
CVAC
91%
SRPT
39%
SGEN
27%
NVO
25%
ICPT
14%
REGN
12%
VRTX
6%
MDGL
0%
CWBR
0%
HEPA
0%
TERN
0%
NVAX
-2%
BNTX
-23%
MRNA
-30%
DNA
-30%
NTLA
-49%
CRSP
-99%
BMRN
-100%
Annual Revenue Growth 20% 7/21 TGTX
778%
RETA
596%
CVAC
126%
ALNY
84%
SRPT
47%
NVAX
23%
NVO
20%
SGEN
15%
BMRN
9%
ICPT
8%
VRTX
7%
REGN
7%
MDGL
0%
CWBR
0%
HEPA
0%
TERN
0%
NTLA
-11%
MRNA
-15%
BNTX
-33%
DNA
-43%
CRSP
-46%
Cash On Hand $7.8 Billion 2/21 BNTX
$11.4B
NVO
$7.8B
VRTX
$4.6B
MRNA
$2.5B
REGN
$1.9B
BMRN
$972.2M
ALNY
$968.5M
DNA
$732.7M
NVAX
$690.6M
MDGL
$494.6M
CRSP
$484.5M
SGEN
$428.6M
SRPT
$383.6M
CVAC
$222.7M
NTLA
$130.8M
ICPT
$102.7M
TERN
$91.5M
TGTX
$82.9M
RETA
$48.8M
CWBR
$6.2M
HEPA
$2.1M
Short Term Debt $804.1 Million 1/21 NVO
$804.1M
BMRN
$505.5M
ALNY
$103.6M
SRPT
$91.5M
BNTX
$38.8M
MRNA
$25.0M
NTLA
$19.0M
CRSP
$16.5M
NVAX
$9.4M
CVAC
$5.6M
RETA
$2.5M
TGTX
$1.3M
MDGL
$557,000
TERN
$249,000
HEPA
$154,090
VRTX
-$0
REGN
-$0
SGEN
-$0
ICPT
-$0
CWBR
-$0
DNA
-$0
Long Term Debt $7.6 Billion 1/21 NVO
$7.6B
ALNY
$2.4B
REGN
$2.0B
MRNA
$1.2B
SRPT
$1.1B
VRTX
$933.4M
BMRN
$594.1M
DNA
$452.3M
BNTX
$241.0M
ICPT
$223.9M
CRSP
$214.9M
NVAX
$168.8M
RETA
$163.5M
SGEN
$113.5M
TGTX
$102.5M
NTLA
$87.3M
MDGL
$0
CWBR
$0
HEPA
$0
CVAC
$0
TERN
$0
PE 36.67 3/21 SRPT
248.15
TGTX
39.42
NVO
36.67
REGN
20.79
BMRN
0.61
NVAX
-1.00
VRTX
-1.00
ALNY
-1.00
RETA
-1.00
SGEN
-1.00
ICPT
-1.00
MDGL
-1.00
NTLA
-1.00
CRSP
-1.00
CWBR
-1.00
HEPA
-1.00
MRNA
-1.00
BNTX
-1.00
CVAC
-1.00
TERN
-1.00
DNA
-1.00
PS 86.64 3/21 MDGL
493.66
RETA
269.17
NVO
86.64
NTLA
33.46
CRSP
21.43
SGEN
18.76
ALNY
14.85
VRTX
11.78
TGTX
10.88
BNTX
7.97
SRPT
7.80
CVAC
7.70
REGN
6.66
MRNA
4.08
ICPT
2.50
DNA
2.30
NVAX
1.77
BMRN
0.02
CWBR
-1.00
HEPA
-1.00
TERN
-1.00
PB 29.30 2/21 RETA
75.22
NVO
29.30
TGTX
21.24
SGEN
16.92
ICPT
11.06
SRPT
10.90
MDGL
8.43
VRTX
8.23
REGN
3.19
TERN
2.74
BMRN
2.38
CRSP
2.18
MRNA
1.76
NTLA
1.58
CVAC
1.47
BNTX
1.24
HEPA
1.03
DNA
0.51
CWBR
0.15
NVAX
0.00
ALNY
0.00
PC 62.41 3/21 RETA
134.44
SGEN
100.70
NVO
62.41
REGN
46.60
TGTX
45.49
ALNY
35.95
SRPT
30.59
VRTX
26.55
MDGL
14.61
BMRN
12.94
NTLA
11.75
CRSP
8.89
MRNA
8.31
ICPT
7.74
TERN
6.55
CVAC
2.73
BNTX
2.27
NVAX
2.11
HEPA
1.73
DNA
0.58
CWBR
0.23
Liabilities to Equity 2.28 3/21 RETA
4.76
ICPT
4.47
NVO
2.28
SRPT
2.18
TGTX
1.26
DNA
0.95
HEPA
0.69
CVAC
0.48
SGEN
0.42
VRTX
0.36
BMRN
0.34
MRNA
0.34
CWBR
0.32
REGN
0.28
MDGL
0.28
NTLA
0.23
CRSP
0.18
BNTX
0.17
TERN
0.06
NVAX
0.00
ALNY
0.00
ROA 0.04 4/21 BMRN
292%
TGTX
24%
REGN
12%
NVO
4%
SRPT
1%
VRTX
-2%
ALNY
-2%
BNTX
-3%
CRSP
-11%
ICPT
-15%
NVAX
-16%
RETA
-16%
SGEN
-21%
MRNA
-37%
TERN
-42%
NTLA
-43%
MDGL
-46%
CVAC
-55%
DNA
-55%
CWBR
-99%
HEPA
-472%
ROE 0.12 6/21 ALNY
2378%
BMRN
390%
NVAX
68%
TGTX
54%
REGN
15%
NVO
12%
SRPT
4%
VRTX
-3%
BNTX
-3%
CRSP
-13%
SGEN
-29%
TERN
-44%
MRNA
-50%
NTLA
-52%
MDGL
-60%
CVAC
-81%
ICPT
-82%
RETA
-94%
DNA
-108%
CWBR
-131%
HEPA
-796%
Current Ratio 1.44 17/21 TERN
18.93
BNTX
7.02
CRSP
6.52
NTLA
5.40
REGN
4.58
MDGL
4.53
CWBR
4.17
BMRN
3.97
MRNA
3.95
VRTX
3.76
SGEN
3.35
CVAC
3.09
HEPA
2.45
DNA
2.05
TGTX
1.79
SRPT
1.46
NVO
1.44
ICPT
1.22
RETA
1.21
ALNY
1.00
NVAX
0.81
Quick Ratio 0.24 21/21 SRPT
248.15
TGTX
39.42
NVO
36.67
REGN
20.79
BMRN
0.61
NVAX
-1.00
VRTX
-1.00
ALNY
-1.00
RETA
-1.00
SGEN
-1.00
ICPT
-1.00
MDGL
-1.00
NTLA
-1.00
CRSP
-1.00
CWBR
-1.00
HEPA
-1.00
MRNA
-1.00
BNTX
-1.00
CVAC
-1.00
TERN
-1.00
DNA
-1.00
Long Term Debt to Equity 0.46 6/21 ICPT}
3.12
RETA}
1.87
SRPT}
1.05
TGTX}
0.58
DNA}
0.54
NVO}
0.46
BMRN}
0.11
CRSP}
0.11
MRNA}
0.11
NTLA}
0.09
REGN}
0.07
VRTX}
0.06
SGEN}
0.04
BNTX}
0.01
MDGL}
0.00
CWBR}
0.00
HEPA}
0.00
CVAC}
0.00
TERN}
0.00
NVAX}
-0.39
ALNY}
-771.20
Debt to Equity 0.51 6/21 ICPT
3.12
RETA
1.90
SRPT
1.27
TGTX
0.63
DNA
0.54
NVO
0.51
BMRN
0.21
CRSP
0.12
NTLA
0.11
MRNA
0.11
REGN
0.10
CVAC
0.10
VRTX
0.06
SGEN
0.04
HEPA
0.04
BNTX
0.01
MDGL
0.00
CWBR
0.00
TERN
0.00
NVAX
-0.54
ALNY
-883.03
Burn Rate 112.36 1/21 NVO
112.36
BMRN
22.62
BNTX
11.41
ICPT
8.75
ALNY
7.05
SRPT
6.21
TERN
4.01
CRSP
3.48
MDGL
3.25
DNA
3.11
CVAC
2.49
SGEN
1.95
MRNA
1.86
CWBR
1.43
VRTX
1.26
NTLA
0.84
HEPA
0.53
RETA
-0.26
REGN
-1.43
NVAX
-4.51
TGTX
-33.83
Cash to Cap 0.02 17/21 CWBR
4.35
DNA
1.73
HEPA
0.58
NVAX
0.47
BNTX
0.44
CVAC
0.37
TERN
0.15
ICPT
0.13
MRNA
0.12
CRSP
0.11
NTLA
0.09
BMRN
0.08
MDGL
0.07
VRTX
0.04
ALNY
0.03
SRPT
0.03
NVO
0.02
REGN
0.02
TGTX
0.02
RETA
0.01
SGEN
0.01
CCR 1.86 3/21 HEPA
2.78
NVAX
1.92
NVO
1.86
CVAC
1.32
MRNA
1.14
VRTX
1.07
BMRN
0.90
TGTX
0.80
CRSP
0.76
TERN
0.71
DNA
0.51
CWBR
0.42
NTLA
0.40
SGEN
0.37
REGN
0.10
MDGL
0.00
RETA
-0.36
ICPT
-1.38
BNTX
-1.85
SRPT
-2.20
ALNY
-6.88
EV to EBITDA 2.21 7/21 SRPT}
1057.61
ALNY}
574.66
TGTX}
427.67
BMRN}
97.81
REGN}
74.65
NVAX}
5.79
NVO}
2.21
CWBR}
-1.00
HEPA}
-1.00
TERN}
-1.00
DNA}
-1.08
CVAC}
-7.33
NTLA}
-11.09
MRNA}
-14.65
CRSP}
-27.70
BNTX}
-28.09
VRTX}
-33.98
MDGL}
-41.42
RETA}
-82.50
SGEN}
-191.83
ICPT}
-331.82
EV to Revenue 2.00 15/21 MDGL
459.91
RETA
273.97
NTLA
32.92
CRSP
20.17
SGEN
18.62
ALNY
15.59
VRTX
11.43
TGTX
10.96
SRPT
8.45
CVAC
7.02
REGN
6.72
BNTX
6.20
MRNA
3.84
ICPT
2.88
NVO
2.00
NVAX
1.22
DNA
0.78
BMRN
0.02
CWBR
-1.00
HEPA
-1.00
TERN
-1.00